Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Engineered outer domain (EOD) of HIV gp120 and mutants thereof

a technology of outer domain and hiv gp120, which is applied in the field of engineered outer domain of hiv gp120 and mutants thereof, can solve the problems that cd4+ t cells seriously impair the body's ability to fight most invaders, and achieve the effect of improving the binding of germline vrc01

Inactive Publication Date: 2014-10-30
UNIV OF WASHINGTON +2
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention relates to improving the binding of a protein called eOD to the VRC01 antibody, which is a target for HIV treatment. The invention focuses on making mutations that improve the antibody's binding and also makes fusions with other proteins to enhance its immunogenicity. Additionally, the invention includes designing cocktails of different eODs to represent the full diversity of HIV sequences within the VRC01 epitope.

Problems solved by technology

The loss of CD4+ T cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Engineered outer domain (EOD) of HIV gp120 and mutants thereof
  • Engineered outer domain (EOD) of HIV gp120 and mutants thereof
  • Engineered outer domain (EOD) of HIV gp120 and mutants thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0116]The invention pertains to the identification, design, synthesis and isolation of mutant eOD proteins disclosed herein as well as nucleic acids encoding the same. The present invention also relates to homologues, derivatives and variants of the sequences of the mutant eOD proteins and nucleic acids encoding the same, wherein it is preferred that the homologue, derivative or variant have at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 98% or at least 99% homology or identity with the sequence of the mutant eOD proteins and nucleic acids encoding the same. It is noted that within this specification, homology to sequences of the mutant proteins and nucleic acids encoding the same refers to the homology of the homologue, derivative or variant to the binding site of the mutant proteins and nucleic acids encoding the same.

[0117]The invention still further relates to nucleic acid seque...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
inhibitory concentrationaaaaaaaaaa
ODaaaaaaaaaa
ODaaaaaaaaaa
Login to View More

Abstract

The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and / or improve binding to mature VRC01 and / or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE[0001]This application is a continuation of international patent application Serial No. PCT / US2012 / 60062 filed 12 Oct. 2012, which published as PCT Publication No. WO 2013 / 056122 on 18 Apr. 2013, which claims priority to U.S. provisional patent application Ser. Nos. 61 / 546,465 and 61 / 699,217 filed Oct. 12, 2011 and Sep. 10, 2012.[0002]Reference is also made to international patent application Serial No. PCT / US2012 / 044996 filed Jun. 29, 2012.[0003]The foregoing applications, and all documents cited therein (“appin cited documents”) and all documents cited or referenced in the appin cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/21C07K14/005
CPCC07K14/005A61K39/21
Inventor HUANG, PO-SSUJARDINE, JOSEPH GRAHAMMENIS, SERGEY V.SCHIEF, JR., WILLIAM RAYKING, NEIL P.
Owner UNIV OF WASHINGTON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products